To meet the demand of this rapidly growing industry, we set ambitious goals to provide competent capacity and capabilities, investing in, building, and ultimately deploying best-in-class viral vector manufacturing platforms that incorporate transformational technologies.

In addition to providing our partners with viral vectors (AAV and LVV) and esoteric viruses, we have also built the requisite PAD and GMP services, capacity, and viral vector platforms which enable these life-saving gene therapies to get to the clinic and to commercialization quicker.

Our partners are already taking advantage of our best-in-class viral vector PAD and GMP biomanufacturing network.